Johnson & Johnson Discontinues Depression Drug Trial With Aticaprant Due To Lack Of Efficacy

Johnson & Johnson discontinued the Phase 3 VENTURA development program evaluating aticaprant as an adjunctive treatment for major depressive disorder (aMDD) due to insufficient efficacy in the target population. The trial confirmed that aticaprant is safe and well-tolerated, and no new safety issues were identified.

The company intends to explore future development opportunities for aticaprant in other areas of high unmet need. Full analyses from the VENTURA development program are underway and will be shared at a future medical meeting.

The clinical trial sought to enroll 840 adults ages 18 to 74. Over 54 weeks, the participants received a . . .